Handelsavisen
prelaunch
Companies Healthcare CDT.O
CD
CDT.O NASDAQ Biotechnology & Medical Research

CDT Equity Inc

$2,78
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
13,5M USD
P/E
EV / Rev
Div yield
Op margin
ROE
114,6 %
Net margin
Debt / equity
-0,32
Beta
52w range
Volume
10,5k
Day range
$0,96–$1,20
Prev close
$0,88
Open
$0,97
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

CDT Equity Inc is a healthcare diagnostics company that provides diagnostic testing and related services to patients and healthcare providers.

Business. CDT Equity Inc (CDT.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability
114,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CDT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CDT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CDT Equity Inc (CDT.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    CDT Equity Inc has a negative equity position of -$3.1 million and a debt-to-equity ratio of -0.32, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidity position is rated as medium, with a current ratio of 1.59, suggesting it can cover short-term obligations but with limited buffer. The enterprise value to EBITDA ratio is -3.39, reflecting the company's unprofitable operations and negative cash flows.

    Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $3.55 million and an operating loss of $2.96 million in the latest period. Return on equity is 1.15%, while return on assets is -0.72%, both well below the industry median for diagnostic companies. The negative operating cash flow of $2.36 million highlights ongoing cash burn that requires close monitoring.

    Geographic and segment exposure data is not available in the current dataset, but the company's business model suggests a focus on domestic diagnostic services with potential regional concentration risks. No specific revenue concentration metrics are disclosed, but the negative equity position implies potential overexposure to a single market or customer segment.

    The company's growth trajectory is constrained by its current financial position. With a market cap of $9.04 million and negative operating income, CDT lacks the financial capacity for meaningful expansion without external financing. The risk assessment indicates low dilution potential, but the negative net cash position after subtracting total debt suggests potential capital raising needs.

    Recent filings and transcripts are not available in the current dataset, but the company's financial statements show consistent operating losses and negative cash flows. The ESG profile reveals a C+ rating with particular weaknesses in the environment pillar, which could impact long-term sustainability.

    The company's risk profile is shaped by its unprofitable operations and negative equity position. While dilution risk is currently low, the negative net cash position after debt suggests potential capital raising needs that could increase dilution risk in the future. The ESG controversies score of 100 indicates no current controversies, but the low environment pillar score suggests potential regulatory risks in the healthcare diagnostics sector.

    Key takeaways
    • CDT Equity Inc has a negative equity position of -$3.1 million and a debt-to-equity ratio of -0.32, indicating a leveraged capital structure.
    • The company reported a net loss of $3.55 million and an operating loss of $2.96 million in the latest period.
    • Return on equity is 1.15%, while return on assets is -0.72%, both well below industry norms for diagnostic companies.
    • The company's growth trajectory is constrained by its current financial position and negative operating cash flows.
    • The ESG profile reveals a C+ rating with particular weaknesses in the environment pillar, which could impact long-term sustainability.
    • The risk assessment indicates low dilution potential, but the negative net cash position after debt suggests potential capital raising needs.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $2,78
    Market cap
    $9.0M
    Enterprise value
    $10.0M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$3.1M
    Net cash
    -$983.0k
    Current ratio
    1.6
    Debt / equity
    -0.3
    ROA
    -72.2%
    ROE
    1.1%
    Cash conversion
    66.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

    Supply chain

    Vendors → CDT ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSCDTCDTCDT Equity Inc2 entitiesCharles River LaboratoBiotechnology & Life-SciUSASTRAZENECA PLCPharmaceuticalsGB
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE114,6 %Best in class
    D/E-0,32Best in class
    Cash Conv0,66Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 55 606 031 sh5 grants5 insiders
    • Regan AndrewDirector, Chief Executive Officer · Pre-Funded Warrants → Common StockDisposed 147 401 @ $0,00conversion · 2026-03-24
    • Taylor Mark Andrew10% owner · Pre-Funded Warrants → Common StockDisposed 51 161 318other · 2026-03-17
    • Farley Chele ChiavacciDirector · Pre-Funded Warrants → Common StockAcquired 1 940 804 @ $0,00grant · 2026-02-19
    • Taylor Mark Andrew10% owner · Pre-Funded Warrants → Common StockDisposed 9 968 931other · 2026-02-19
    • Regan AndrewDirector, Chief Executive Officer, 10% owner · Pre-Funded Warrants → Common StockAcquired 3 685 815 @ $0,00grant · 2025-12-08
    • Fry Simon JeremyDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05
    • Lewis-Hall Freda CDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05
    • Farley Chele ChiavacciDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $1,89grant · 2025-08-05

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    Source documents
    • CDT Equity Inc Market data — financials · 2026-05-27
    • CDT Equity Inc Market data — ESG · 2026-05-27

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 4 sellsnet -$2,9M6 insiders · last 365d
    • Taylor Mark Andrew10% owner · Common StockSold 593 289 @ $1,40$829K · 2026-06-18
    • Taylor Mark Andrew10% owner · Common StockSold 1 464 711 @ $1,44$2,1M · 2026-06-18
    • Taylor Mark Andrew10% owner · Common StockSold 5 000 @ $0,75$4K · 2026-06-18
    • Taylor Mark Andrew10% owner · Common StockSold 5 000 @ $0,71$4K · 2026-06-18
    • Regan AndrewDirector, Chief Executive Officer · Common StockOther 100 000 @ $1,90$190K · 2026-05-13
    • Regan AndrewDirector, Chief Executive Officer · Common StockOther 147 401 · 2026-03-24
    • Taylor Mark Andrew10% owner · Common StockOther 51 420 358 · 2026-03-17
    • Farley Chele ChiavacciDirector · Common StockOther 10 553 @ $1,04$11K · 2026-02-19
    • Taylor Mark Andrew10% owner · Common StockOther 46 902 · 2026-02-19
    • Regan AndrewDirector, Chief Executive Officer, 10% owner · Common StockOther 224 800 @ $1,79$402K · 2025-12-08
    • Bligh JamesDirector, CFO · Common StockOther 480 000 · 2025-09-19
    • Regan AndrewDirector, Chief Executive Officer, 10% owner · Common StockOther 1 120 000 @ $0,69$769K · 2025-09-19
    • Lewis-Hall Freda CDirector · Common StockOther 35 000 · 2025-08-12
    • Fry Simon JeremyDirector · Common StockOther 35 000 · 2025-08-12
    • Farley Chele ChiavacciDirector · Common StockOther 35 000 · 2025-08-12

    Short positioning

    185.3Kshares short+10.5% vs prior
    1days to cover
    39.9%short of daily vol
    442fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CDT.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    CDTCRL.OAZN.LBiotechnology
    This companySectorVendors

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 34.7%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.79xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 49.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -138.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -60.7%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -120.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 98.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 98.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 172.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): 547.1%Derived (calculated)
    • Return on assets (FY 2025-12-31): -694.2%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.34xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
    • Total assets (annual): USD 5.65MSEC XBRL filing
    • Operating cash flow (annual): USD -15.55MSEC XBRL filing
    • Current liabilities (annual): USD 12.82MSEC XBRL filing
    • Cash & equivalents (annual): USD 1.51MSEC XBRL filing
    • Total operating expenses (annual): USD 36.76MSEC XBRL filing
    • Pre-tax income (annual): USD -39.22MSEC XBRL filing
    • Net income (annual): USD -39.22MSEC XBRL filing
    • R&D expense (annual): USD 5.05MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1.18KSEC XBRL filing
    • Operating income (annual): USD -36.76MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-02 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-02 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-07-02EVENTQ3 2026 earnings (expected) estimated date
    2026-06-25 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-06-25EVENTQ2 2026 earnings (expected) estimated date
    2026-06-18 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $2.9M
    2026-06-18INSIDERTaylor Mark Andrew sold 593.3k sh — 10% owner ~$829k
    2026-06-18INSIDERTaylor Mark Andrew sold 1.46M sh — 10% owner ~$2.11M
    2026-06-18INSIDERTaylor Mark Andrew sold 5.0k sh — 10% owner ~$4k
    2026-06-16FILING8-K filing →
    2026-05-28FILING8-K filing →
    2026-05-15FILING8-K filing →
    2026-05-13 00:00 UTCINSIDER1 insider transaction — 2026-05 · net buy $190k
    2026-05-13INSIDERRegan Andrew transacted 100.0k sh — Director, Chief Executive Officer ~$190k
    2026-05-01FILING424B3 filing →
    2026-04-27FILING8-K filing →
    2026-04-15FILING10-K filing →
    2026-04-02FILING424B5 filing →
    2026-03-25FILING8-K filing →
    2026-03-24 00:00 UTCINSIDER4 insider transactions — 2026-03 2 derivative
    2026-03-24INSIDERRegan Andrew transacted 147.4k sh — Director, Chief Executive Officer
    2026-03-24INSIDERRegan Andrew disposed of 147.4k sh Pre-Funded Warrants — Director, Chief Executive Officer
    2026-03-18FILING8-K filing →
    2026-03-17INSIDERTaylor Mark Andrew transacted 51.42M sh — 10% owner
    2026-03-17INSIDERTaylor Mark Andrew disposed of 51.16M sh Pre-Funded Warrants — 10% owner
    2026-03-09FILING8-K filing →
    2026-03-06FILINGDEF 14A filing →
    2026-02-24FILING8-K filing →
    2026-02-19 00:00 UTCINSIDER4 insider transactions — 2026-02 2 derivative
    2026-02-19INSIDERFarley Chele Chiavacci transacted 10.6k sh — Director ~$11k
    2026-02-19INSIDERTaylor Mark Andrew transacted 46.9k sh — 10% owner
    2026-02-19INSIDERTaylor Mark Andrew disposed of 9.97M sh Pre-Funded Warrants — 10% owner
    2026-02-19INSIDERFarley Chele Chiavacci acquired 1.94M sh Pre-Funded Warrants — Director
    2025-12-08 00:00 UTCINSIDER2 insider transactions — 2025-12 · net buy $402k 1 derivative
    2025-12-08INSIDERRegan Andrew transacted 224.8k sh — Director, Chief Executive Officer, 10% owner ~$402k
    2025-12-08INSIDERRegan Andrew acquired 3.69M sh Pre-Funded Warrants — Director, Chief Executive Officer, 10% owner
    2025-09-19 00:00 UTCINSIDER2 insider transactions — 2025-09 · net buy $769k
    2025-09-19INSIDERBligh James transacted 480.0k sh — Director, CFO
    2025-09-19INSIDERRegan Andrew transacted 1.12M sh — Director, Chief Executive Officer, 10% owner ~$769k
    Showing the 40 most recent of 48 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage